Objective To analyze the long-term stability of domestic keratoprosthesis (Kpro) after its application in rabbits′ corneas. Methods In this experimental study, domestic permanent modified keratoprosthesis (Moroz Kpro) were implanted in the right eyes of 10 rabbits. The left eyes served as control. Surgery involved two steps: Successively implantation of titanium frame first and then the implantation of optical cylinder. In the first stage, the third eyelid (cartilage, equivalent to) was removed and used as reinforcement of corneal surface and then autologous conjunctival was covered at the surface (Stage 1); secondly, an optical cylinder was implanted 3 months after the first stage (Stage 2). Postoperative observation follow up for 6 months. Postoperative antibiotic eye drops were given to prevent infection. Finally the corneas were observed histopathological, compared with the left eyes. Results One rabbit died because of intraoperative anesthesia during the operation of stage 2. The other 9 rabbits survived till the end of 6-month follow up. These Kpros retained till the end without severe complications, such as corneal melting, aqueous humor leakage, high intraocular pressure or infection etc. Biopsy specimen showed: The cartilages were in place; the frame and the surrounding tissue combined closely; there was a more active proliferation of fibrous tissue around the Kpro, and the keratitis reactions were very slight. The left eyes were normal. Conclusion Domestic keratoprosthesis has a good biocompatibility and stability after the application in the cornea of rabbits. The application of cartilage and autologous conjunctival play an important role in the success of keratoprosthesis retention.
孟晓丽,黄一飞,王丽强,等. 国产化人工角膜植入兔眼的稳定性评估. 中华眼视光学与视觉科学杂志, 2016, 18(4):203-208. DOI:DOI:10.3760/cma.j.issn.1674-845X.2016.04.003.
Meng Xiaoli*,Huang Yifei,Wang Liqiang,et al. The assessment of stability of the domestic keratoprosthesis implanted into rabbit′s cornea. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(4):203-208.
V?觟lker-Dieben HJ, Kok-van ACC, Lansbergen Q, et al. Different influences on corneal graft survival in 539 transplants[J]. Acta Ophthalmol (Copenh),1982,60(2):190-202.
[2]
Williams KA, Muehlberg SM, Lewis RF, et al. How successful is corneal transplantation? A report from the Australian Corneal Graft Register[J]. Eye (Lond),1995,9 (Pt 2):219-227. DOI:10.1038/eye.1995.43.
[3]
Barber JC. Keratoprosthesis: past and present[J]. Int Ophthalmol Clin,1988,28(2):103-109.
[4]
Hicks CR, Fitton JH, Chirila TV, et al. Keratoprostheses: advancing toward a true artificial cornea[J]. Surv Ophthalmol,1997,42(2):175-189.
[5]
Chirila TV, Hicks CR .The origins of the artificial cornea: Pellier de Quengsy and his contribution to the modern concept of keratoprosthesis[J]. Gesnerus,1999,56(1-2):96-106.
[6]
Aldave AJ, Sangwan VS, Basu S, et al. International results with the Boston type I keratoprosthesie[J]. Ophthalmology,2012,119(8):1530-1538. DOI:10.1016/j.ophtha.2012.02.015.
[7]
Ciolino JB, Belin MW, Todani A, et al. Retention of the Boston keratoprosthesis type 1: multicenter study results[J]. Ophthalmology, 2013,120(6):1195-1200. DOI:10.1016/j.ophtha.2012.11.025.
Jirásková N, Rozsival P, Burova M, et al. AlphaCor artificial cornea: clinical outcome[J]. Eye (Lond),2011,25(9):1138-1146. DOI:10.1038/eye.2011.122.
[10]
Lee RM, Ong GL, Lam FC, et al. Optical functional performance of the osteo-odonto-keratoprosthesis[J]. Cornea,2014,33(10):1038-1045. DOI:10.1097/ICO.0000000000000235.
[11]
Huang Y, Yu J, Liu L, et al. Moscow eye microsurgery complex in Russia keratoprosthesis in Beijing[J]. Ophthalmology,2011,118(1):41-46. DOI:10.1016/j.ophtha.2010.05.019.
[12]
Huang Y, Dong Y, Wang L, et al. Long-term outcomes of MICOF keratoprosthesis in the end stage of autoimmune dry eyes: an experience in China[J].Br J Ophthalmol,2012,96(1):28-33. DOI:10.1136/bjo.2010.193029.
Wang L, Huang Y, Du G, et al. Long-term outcomes and complications of Moscow eye microsurgery complex in Russia (MICOF) keratoprosthesis following ocular surface burns: clinical experience in China[J]. Br J Ophthalmol,2015,99(12):1669-1674. DOI:10.1136/bjophthalmol-2014-306115.
[15]
Yu TS, Liu H, Hui K. A case-control study of eye injuries in the workplace in Hong Kong[J]. Ophthalmology,2004,111(1):70-74. DOI:10.1016/j.ophtha.2003.05.018.
[16]
Hong J, Qiu T, Wei A, et al. Clinical characteristics and visual outcome of severe ocular chemical injuries in Shanghai[J]. Ophthalmology,2010,117(12):2268-2272. DOI:10.1016/j.ophtha.2010. 03.050.
[17]
Hayashi K, Hayashi H. Intraocular lens factors that may affect anterior capsule contraction[J]. Ophthalmology,2005,112(2):286-292. DOI:10.1016/j.ophtha.2004.11.013.
[18]
Alió JL, Mulet ME, Haroun H, et al. Five year follow up of biocolonisable microporous fluorocarbon haptic (BIOKOP) keratoprosthesis implantation in patients with high risk of corneal graft failure[J]. Br J Ophthalmol,2004,88(12):1585-1589. DOI:10.1136/bjo.2004.046375.
[19]
Zerbe BL, Belin MW, Ciolino JB. Results from the multicenter Boston Type 1 Keratoprosthesis Study[J]. Ophthalmology,2006, 113(10):1779.e1-7. DOI:10.1016/j.ophtha.2006.05.015.
[20]
Aldave AJ, Kamal KM, Vo RC, et al. The Boston type I keratoprosthesis: improving outcomes and expanding indications[J]. Ophthalmology,2009,116(4):640-651. DOI:10.1016/j.ophtha.2008.12.058.
[21]
Akpek EK, Harissi-Dagher M, Petrarca R, et al. Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study[J]. Am J Ophthalmol,2007,144(2):227-231. DOI:10.1016/j.ajo.2007.04.036.
[22]
Sayegh RR, Ang LP, Foster CS,et al. The Boston keratoprosthesis in Stevens-Johnson syndrome[J]. Am J Ophthalmol,2008,145(3):438-444. DOI:10.1016/j.ajo.2007.11.002.
[23]
Bradley JC, Hernandez EG, Schwab IR, et al. Boston type 1 keratoprosthesis: the university of california davis experience[J].Cornea,2009,28(3):321-327. DOI:10.1097/ICO.0b013e31818b8bfa.
[24]
Li JY, Greiner MA, Brandt JD, et al. Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis[J]. Am J Ophthalmol,2011,152(2):209-218. DOI: 10.1016/j.ajo.2011.01.034.
[25]
Sivaraman KR, Hou JH, Allemann N, et al. Retroprosthetic membrane and risk of sterile keratolysis in patients with type I Boston Keratoprosthesis[J]. Am J Ophthalmol,2013,155(5):814-822. DOI:10.1016/j.ajo.2012.11.019.
[26]
Gomaa A, Comyn O, Liu C. Keratoprostheses in clinical practice-a review[J]. Clin Experiment Ophthalmol,2010,38(2):211-224. DOI: 10.1111/j.1442-9071.2010.02231.x.
[27]
Wang L, Jeong KJ, Chiang HH, et al. Hydroxyapatite for keratoprosthesis biointegration[J]. Invest Ophthalmol Vis Sci,2011,52(10):7392-7399. DOI:10.1167/iovs.11-7601.